Stockscreener 앱 받기
1.79
0.56%
-0.01
시간 외 거래:
1.82
0.03
+1.68%
전일 마감가:
$1.80
열려 있는:
$1.78
하루 거래량:
692.79K
Relative Volume:
0.40
시가총액:
$236.34M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-3.6367
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+13.29%
1개월 성능:
-4.79%
6개월 성능:
+10.49%
1년 성능:
-2.72%
1일 변동 폭
$1.745
$1.83
1주일 범위
$1.59
$1.83
52주 변동 폭
$1.33
$2.365
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.79 | 237.66M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
Five new Inhibikase hires get stock options priced at $1.68 - Stock Titan
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart
Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView
Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - The Manila Times
Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - Moomoo
Surprises Report: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (IKT) Gains New Coverage with 'Buy' Rati - GuruFocus
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy - marketscreener.com
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital - Defense World
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4%Still a Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% – Still a Buy? - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock Surge: What’s Driving the 13% Jump Today? - Creative Learning Guild
Inhibikase (IKT) R&D president forfeits 338,282 milestone-based shares - Stock Titan
Inhibikase (IKT) director Amit Munshi forfeits 19,089 milestone-based shares - Stock Titan
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade
Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com
IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade
Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com
Certain Warrants of Inhibikase Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2026. - marketscreener.com
ADAR1 group discloses 9.9% Inhibikase (IKT) ownership via shares and warrants - Stock Titan
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.11%
자본화:
|
볼륨(24시간):